<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35805149</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Gene Therapy in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2066</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11132066</ELocationID><Abstract><AbstractText>Since the discovery of <i>Cu/Zn superoxide dismutase</i> (<i>SOD1</i>) gene mutation, in 1993, as the first genetic abnormality in amyotrophic lateral sclerosis (ALS), over 50 genes have been identified as either cause or modifier in ALS and ALS/frontotemporal dementia (FTD) spectrum disease. Mutations in <i>C9orf72</i>, <i>SOD1</i>, <i>TAR DNA binding protein 43</i> (<i>TARDBP</i>), and <i>fused in sarcoma</i> (<i>FUS</i>) genes are the four most common ones. During the last three decades, tremendous effort has been made worldwide to reveal biological pathways underlying the pathogenesis of these gene mutations in ALS/FTD. Accordingly, targeting etiologic genes (i.e., gene therapies) to suppress their toxic effects have been investigated widely. It includes four major strategies: (i) removal or inhibition of abnormal transcribed RNA using microRNA or antisense oligonucleotides (ASOs), (ii) degradation of abnormal mRNA using RNA interference (RNAi), (iii) decrease or inhibition of mutant proteins (e.g., using antibodies against misfolded proteins), and (iv) DNA genome editing with methods such as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (CRISPR/Cas). The promising results of these studies have led to the application of some of these strategies into ALS clinical trials, especially for <i>C9orf72</i> and <i>SOD1</i>. In this paper, we will overview advances in gene therapy in ALS/FTD, focusing on <i>C9orf72</i>, <i>SOD1</i>, <i>TARDBP</i>, and <i>FUS</i> genes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Ton</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2119-9015</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Je</LastName><ForeName>Goun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacut</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keyhanian</LastName><ForeName>Kiandokht</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghasemi</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1384-9826</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 HD060848</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Cu/Zn superoxide dismutase (SOD1)</Keyword><Keyword MajorTopicYN="N">TAR DNA binding protein 43 (TARDBP)</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">fused in sarcoma (FUS)</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35805149</ArticleId><ArticleId IdType="pmc">PMC9265980</ArticleId><ArticleId IdType="doi">10.3390/cells11132066</ArticleId><ArticleId IdType="pii">cells11132066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peters O.M., Ghasemi M., Brown R.H., Jr. Emerging mechanisms of molecular pathology in ALS. J. Clin. Investig. 2015;125:1767&#x2013;1779. doi: 10.1172/JCI71601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI71601</ArticleId><ArticleId IdType="pmc">PMC4463186</ArticleId><ArticleId IdType="pubmed">25932674</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E., Ticozzi N., Mandrioli J. Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder. Front. Neurosci. 2019;13:175. doi: 10.3389/fnins.2019.00175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00175</ArticleId><ArticleId IdType="pmc">PMC6421303</ArticleId><ArticleId IdType="pubmed">30914912</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Brown R.H., Jr. Genetics of Amyotrophic Lateral Sclerosis. Cold Spring Harb. Perspect. Med. 2018;8:a024125. doi: 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S., King A., Troakes C., Smith B., Maekawa S., Bodi I., Rogelj B., Al-Chalabi A., Hortob&#xe1;gyi T., Shaw C.E. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 2011;122:691&#x2013;702. doi: 10.1007/s00401-011-0911-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0911-2</ArticleId><ArticleId IdType="pubmed">22101323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Hewitt C., Highley J.R., Brockington A., Milano A., Man S., Martindale J., Hartley J., Walsh T., Gelsthorpe C., et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain J. Neurol. 2012;135:751&#x2013;764. doi: 10.1093/brain/awr365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr365</ArticleId><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper L.J., Raaphorst J., Aronica E., Baas F., de Haan R., de Visser M., Troost D. Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: A systematic neuropathological review. Neuropathol. Appl. Neurobiol. 2016;42:547&#x2013;560. doi: 10.1111/nan.12284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12284</ArticleId><ArticleId IdType="pubmed">26373655</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J., Dopper E.G.P., Cohn-Hokke P.E., Hukema R.K., Nicolaou N., Seelaar H., de Graaf J.R.A., de Koning I., van Schoor N.M., Deeg D.J.H., et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain J. Neurol. 2012;135:723&#x2013;735. doi: 10.1093/brain/awr353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr353</ArticleId><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Ravits J. Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Neurotherapeutics. 2019;16:1115&#x2013;1132. doi: 10.1007/s13311-019-00797-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00797-2</ArticleId><ArticleId IdType="pmc">PMC6985338</ArticleId><ArticleId IdType="pubmed">31667754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013;16:571&#x2013;579. doi: 10.1038/nn.3357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3357</ArticleId><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipi T., Hermanova Z., Tureckova J., Vanatko O., Anderova A.M. Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. J. Clin. Med. 2020;9:261. doi: 10.3390/jcm9010261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010261</ArticleId><ArticleId IdType="pmc">PMC7020059</ArticleId><ArticleId IdType="pubmed">31963681</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: What do we really know? Nat. Rev. Neurol. 2011;7:603&#x2013;615. doi: 10.1038/nrneurol.2011.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Chen W., Hong S.T., Boycott K.M., Gorrie G.H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211&#x2013;215. doi: 10.1038/nature10353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10353</ArticleId><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Langenhove T., van der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S., et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study. Lancet Neurol. 2012;11:54&#x2013;65. doi: 10.1016/S1474-4422(11)70261-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70261-7</ArticleId><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Krainer A.R., Cleveland D.W. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu. Rev. Neurosci. 2019;42:385&#x2013;406. doi: 10.1146/annurev-neuro-070918-050501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050501</ArticleId><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles S., Velde C.V. Misfolded SOD1 and ALS: Zeroing in on mitochondria. Amyotroph. Lateral. Scler. 2012;13:333&#x2013;340. doi: 10.3109/17482968.2012.648645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.648645</ArticleId><ArticleId IdType="pubmed">22471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Sayana P., Zhang X., Le W. Genetics of amyotrophic lateral sclerosis: An update. Mol. Neurodegener. 2013;8:28. doi: 10.1186/1750-1326-8-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-28</ArticleId><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton-Stasyshyn R.K., Saccon R.A., Fratta P., Fisher E.M. SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes. Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry. 2015;21:519&#x2013;529. doi: 10.1177/1073858414561795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858414561795</ArticleId><ArticleId IdType="pubmed">25492944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling A.C., Schulz J.B., Brown R.H., Jr., Beal M.F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 1993;61:2322&#x2013;2325. doi: 10.1111/j.1471-4159.1993.tb07478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb07478.x</ArticleId><ArticleId IdType="pubmed">8245985</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O., Powell J.F., Andersen P.M., Al-Chalabi A. ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012;33:1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Penco S., Lunetta C., Mosca L., Maestri E., Avemaria F., Tarlarini C., Patrosso M.C., Marocchi A., Corbo M. Phenotypic heterogeneity in a SOD1 G93D Italian ALS family: An example of human model to study a complex disease. J. Mol. Neurosci. 2011;44:25&#x2013;30. doi: 10.1007/s12031-010-9480-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9480-4</ArticleId><ArticleId IdType="pubmed">21120636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Feng X., Li X., Mou J., Liu H., Chen J., Wu J. The G41D mutation in SOD1-related amyotrophic lateral sclerosis exhibits phenotypic heterogeneity among individuals: A case report and literature review. Medicine. 2022;101:e28771. doi: 10.1097/MD.0000000000028771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000028771</ArticleId><ArticleId IdType="pmc">PMC8830837</ArticleId><ArticleId IdType="pubmed">35147103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., McKenna-Yasek D., Sapp P.E., Chin W., Geller B., Hayden D.L., Schoenfeld D.A., Hosler B.A., Horvitz H.R., Brown R.H. Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis. Ann. Neurol. 1997;41:210&#x2013;221. doi: 10.1002/ana.410410212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410212</ArticleId><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X.-H., Sun H., Nichols J.G., Crooke S.T. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Mol. Ther. 2017;25:2075&#x2013;2092. doi: 10.1016/j.ymthe.2017.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.06.002</ArticleId><ArticleId IdType="pmc">PMC5589097</ArticleId><ArticleId IdType="pubmed">28663102</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1723&#x2013;1732. doi: 10.1056/NEJMoa1702752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Miller T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H., et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Investig. 2006;116:2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations (SOD-1). ClinicalTrials.gov Identifier: NCT01041222. 2012.  [(accessed on 20 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT01041222.</Citation></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen  Biogen Announces Topline Results from the Tofersen Phase 3 Study and Its Open-Label Extension in SOD1-ALS. 2021.  [(accessed on 20 June 2022)].  Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-tofersen-phase-3-study-and-its#:~:text=%E2%80%9CData%20from%20the%20tofersen%20Phase,Research%20and%20Development%20at%20Biogen.</Citation></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarrott J.M., Herranz-Mart&#xed;n S., Alrafiah A.R., Shaw P.J., Azzouz M. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin. Biol. Ther. 2015;15:935&#x2013;947. doi: 10.1517/14712598.2015.1044894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2015.1044894</ArticleId><ArticleId IdType="pubmed">25959569</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457:426&#x2013;433. doi: 10.1038/nature07758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07758</ArticleId><ArticleId IdType="pmc">PMC2702667</ArticleId><ArticleId IdType="pubmed">19158789</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Salazar D.L., Likhite S., Ferraiuolo L., Ditsworth D., Ilieva H., Meyer K., Schmelzer L., Braun L., Cleveland D.W., et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. J. Am. Soc. Gene Ther. 2013;21:2148&#x2013;2159. doi: 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen G.M., Gowing G. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J. Neurosci. 2014;34:15587&#x2013;15600. doi: 10.1523/JNEUROSCI.2037-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2037-14.2014</ArticleId><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L., Todeasa S.H., Cabrera G.T., Salameh J.S., ElMallah M.K., Mueller C., Brown R.H., Jr., Sena-Esteves M. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann. Neurol. 2016;79:687&#x2013;700. doi: 10.1002/ana.24618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24618</ArticleId><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang E.J., Reichardt L.F. Neurotrophins: Roles in neuronal development and function. Annu. Rev. Neurosci. 2001;24:677&#x2013;736. doi: 10.1146/annurev.neuro.24.1.677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.677</ArticleId><ArticleId IdType="pmc">PMC2758233</ArticleId><ArticleId IdType="pubmed">11520916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H., Hu H., Duan W., Liu Y., Tan G., Li Z., Liu Y., Deng B., Song X., Wang W., et al. Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1(G93A) ALS Mouse Model via Upregulation of D-Amino Acid Oxidase. Mol. Neurobiol. 2018;55:682&#x2013;695. doi: 10.1007/s12035-016-0335-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0335-z</ArticleId><ArticleId IdType="pubmed">27995572</ArticleId></ArticleIdList></Reference><Reference><Citation>Allodi I., Comley L., Nichterwitz S., Nizzardo M., Simone C., Benitez J.A., Cao M., Corti S., Hedlund E. Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. Sci. Rep. 2016;6:25960. doi: 10.1038/srep25960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25960</ArticleId><ArticleId IdType="pmc">PMC4867585</ArticleId><ArticleId IdType="pubmed">27180807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Duan W., Wang W., Di W., Liu Y., Liu Y., Li Z., Hu H., Lin H., Cui C., et al. scAAV9-VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway. Brain Res. 2016;1648:1&#x2013;10. doi: 10.1016/j.brainres.2016.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.06.043</ArticleId><ArticleId IdType="pubmed">27392886</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Treleaven C.M., Fidler J.A., Hester M., Haidet A., Handy C., Rao M., Eagle A., Matthews J.C., Taksir T.V., et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. J. Am. Soc. Gene Ther. 2010;18:2075&#x2013;2084. doi: 10.1038/mt.2010.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.206</ArticleId><ArticleId IdType="pmc">PMC2997594</ArticleId><ArticleId IdType="pubmed">20859261</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich M., Zhang F. Applications of CRISPR-Cas systems in neuroscience. Nat. Rev. Neurosci. 2016;17:36&#x2013;44. doi: 10.1038/nrn.2015.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2015.2</ArticleId><ArticleId IdType="pmc">PMC4899966</ArticleId><ArticleId IdType="pubmed">26656253</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 2017;3:eaar3952. doi: 10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952</ArticleId><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Guo M., Yi L., Liu Y., Li Z., Ma Y., Zhang G., Liu Y., Bu H., Song X., et al. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2020;27:157&#x2013;169. doi: 10.1038/s41434-019-0116-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-019-0116-1</ArticleId><ArticleId IdType="pubmed">31819203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C.K.W., Gapinske M., Brooks A.K., Woods W.S., Powell J.E., Zeballos C.M., Winter J., Perez-Pinera P., Gaj T. Treatment of a Mouse Model of ALS by In Vivo Base Editing. Mol. Ther. J. Am. Soc. Gene Ther. 2020;28:1177&#x2013;1189. doi: 10.1016/j.ymthe.2020.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.005</ArticleId><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H.P., Van Broeckhoven C., van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34:404&#x2013;423. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Keyhanian K., Douthwright C. Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Cells. 2021;10:249. doi: 10.3390/cells10020249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020249</ArticleId><ArticleId IdType="pmc">PMC7912327</ArticleId><ArticleId IdType="pubmed">33525344</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler A.R., Donnelly C.J., Rothstein J.D. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat. Rev. Neurosci. 2016;17:383&#x2013;395. doi: 10.1038/nrn.2016.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.38</ArticleId><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A., Al Khleifat A., Jones A.R., Sproviero W., Shatunov A., Opie-Martin S., Morrison K.E., Shaw P.J., Shaw C.E., Fogh I., et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol. Commun. 2019;7:115. doi: 10.1186/s40478-019-0724-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0724-4</ArticleId><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammack A.J., Atassi N., Hyman T., van den Berg L.H., Harms M., Baloh R.H., Brown R.H., van Es M.A., Veldink J.H., de Vries B.S., et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019;93:e1605&#x2013;e1617. doi: 10.1212/WNL.0000000000008359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008359</ArticleId><ArticleId IdType="pmc">PMC6946465</ArticleId><ArticleId IdType="pubmed">31578300</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S., Elamin M., Bede P., Shatunov A., Walsh C., Corr B., Heverin M., Jordan N., Kenna K., Lynch C., et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240. doi: 10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D.J., McMillan C.T., Brettschneider J., Libon D.J., Powers J., Rascovsky K., Toledo J.B., Boller A., Bekisz J., Chandrasekaran K., et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:163&#x2013;169. doi: 10.1136/jnnp-2012-303507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303507</ArticleId><ArticleId IdType="pmc">PMC3543474</ArticleId><ArticleId IdType="pubmed">23117491</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Boill&#xe9;e S., Le Ber I., Seilhean D., Teyssou E., Giraudeau M., Moigneu C., Vandenberghe N., Danel-Brunaud V., Corcia P., et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J. Med. Genet. 2012;49:258&#x2013;263. doi: 10.1136/jmedgenet-2011-100699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Borghero G., Restagno G., Mora G., Drepper C., Traynor B.J., Sendtner M., Brunetti M., Ossola I., Calvo A., et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain J. Neurol. 2012;135:784&#x2013;793. doi: 10.1093/brain/awr366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr366</ArticleId><ArticleId IdType="pmc">PMC3286333</ArticleId><ArticleId IdType="pubmed">22366794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q., Jiang J., Gendron T.F., McAlonis-Downes M., Jiang L., Taylor A., Diaz Garcia S., Ghosh Dastidar S., Rodriguez M.J., King P., et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat. Neurosci. 2020;23:615&#x2013;624. doi: 10.1038/s41593-020-0619-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0619-5</ArticleId><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Lin S., Staats K.A., Li Y., Chang W.-H., Hung S.-T., Hendricks E., Linares G.R., Wang Y., Son E.Y., et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 2018;24:313&#x2013;325. doi: 10.1038/nm.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C.J., Zhang P.W., Pham J.T., Haeusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.R., Jiang J., Watt A.T., Chun S., Katz M., et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Chew J., Stankowski J.N., Hayes L.R., Zhang Y.-J., Prudencio M., Carlomagno Y., Daughrity L.M., Jansen-West K., Perkerson E.A., et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D., O&#x2019;Rourke J.G., Meera P., Muhammad A.K., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A., et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013;5:208ra149. doi: 10.1126/scitranslmed.3007529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H., Moazami M.P., Yang H., McKenna-Yasek D., Douthwright C.L., Pinto C., Metterville J., Shin M., Sanil N., Dooley C., et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 2022;28:117&#x2013;124. doi: 10.1038/s41591-021-01557-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01557-6</ArticleId><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen  Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis. 2022.  [(accessed on 20 June 2022)].  Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results.</Citation></Reference><Reference><Citation>Hu J., Rigo F., Prakash T.P., Corey D.R. Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs. Nucleic Acid Ther. 2017;27:87&#x2013;94. doi: 10.1089/nat.2016.0655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2016.0655</ArticleId><ArticleId IdType="pmc">PMC5372765</ArticleId><ArticleId IdType="pubmed">28005462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Liu J., Li L., Gagnon K.T., Corey D.R. Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus. Chem. Biol. 2015;22:1505&#x2013;1511. doi: 10.1016/j.chembiol.2015.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2015.09.016</ArticleId><ArticleId IdType="pmc">PMC4659491</ArticleId><ArticleId IdType="pubmed">26584779</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouet V., Perrin V., Hassig R., Dufour N., Auregan G., Alves S., Bonvento G., Brouillet E., Luthi-Carter R., Hantraye P., et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 2009;65:276&#x2013;285. doi: 10.1002/ana.21569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21569</ArticleId><ArticleId IdType="pubmed">19334076</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanek L.M., Sardi S.P., Mastis B., Richards A.R., Treleaven C.M., Taksir T., Misra K., Cheng S.H., Shihabuddin L.S. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington&#x2019;s disease. Hum. Gene Ther. 2014;25:461&#x2013;474. doi: 10.1089/hum.2013.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2013.200</ArticleId><ArticleId IdType="pmc">PMC4028091</ArticleId><ArticleId IdType="pubmed">24484067</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Garc&#xed;a-Osta A., Miniarikova J., Cuadrado-Tejedor M., Espelosin M., Ursua S., Petry H., van Deventer S.J., Evers M.M., et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol. Ther. Nucleic Acids. 2019;16:26&#x2013;37. doi: 10.1016/j.omtn.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Miniarikova J., van der Zon T., Snapper J., Kolder I., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic Acids. 2019;14:593&#x2013;608. doi: 10.1016/j.omtn.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z., Zhang Y., Gendron T.F., Bauer P.O., Chew J., Yang W.Y., Fostvedt E., Jansen-West K., Belzil V.V., Desaro P., et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014;83:1043&#x2013;1050. doi: 10.1016/j.neuron.2014.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.07.041</ArticleId><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamiri B., Reddy K., Macgregor R.B., Jr., Pearson C.E. TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J. Biol. Chem. 2014;289:4653&#x2013;4659. doi: 10.1074/jbc.C113.502336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C113.502336</ArticleId><ArticleId IdType="pmc">PMC3931028</ArticleId><ArticleId IdType="pubmed">24371143</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R., Balendra R., Moens T.G., Preza E., Wilson K.M., Heslegrave A., Woodling N.S., Niccoli T., Gilbert-Jaramillo J., Abdelkarim S., et al. G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol. Med. 2018;10:22&#x2013;31. doi: 10.15252/emmm.201707850.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707850</ArticleId><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Alniss H., Zamiri B., Khalaj M., Pearson C.E., Macgregor R.B., Jr. Thermodynamic and spectroscopic investigations of TMPyP4 association with guanine- and cytosine-rich DNA and RNA repeats of C9orf72. Biochem. Biophys. Res. Commun. 2018;495:2410&#x2013;2417. doi: 10.1016/j.bbrc.2017.12.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.12.108</ArticleId><ArticleId IdType="pubmed">29274339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z.-F., Ursu A., Childs-Disney J.L., Guertler R., Yang W.-Y., Bernat V., Rzuczek S.G., Fuerst R., Zhang Y.-J., Gendron T.F., et al. The Hairpin Form of r(G(4)C(2))(exp) in c9ALS/FTD Is Repeat-Associated Non-ATG Translated and a Target for Bioactive Small Molecules. Cell Chem. Biol. 2019;26:179&#x2013;190e12. doi: 10.1016/j.chembiol.2018.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2018.10.018</ArticleId><ArticleId IdType="pmc">PMC6386614</ArticleId><ArticleId IdType="pubmed">30503283</ArticleId></ArticleIdList></Reference><Reference><Citation>Skourti-Stathaki K., Proudfoot N.J., Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol. Cell. 2011;42:794&#x2013;805. doi: 10.1016/j.molcel.2011.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2011.04.026</ArticleId><ArticleId IdType="pmc">PMC3145960</ArticleId><ArticleId IdType="pubmed">21700224</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuce O., West S.C. Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response. Mol. Cell. Biol. 2013;33:406&#x2013;417. doi: 10.1128/MCB.01195-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01195-12</ArticleId><ArticleId IdType="pmc">PMC3554130</ArticleId><ArticleId IdType="pubmed">23149945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.Z., Bennett C.L., Huynh H.M., Blair I.P., Puls I., Irobi J., Dierick I., Abel A., Kennerson M.L., Rabin B.A., et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4) Am. J. Hum. Genet. 2004;74:1128&#x2013;1135. doi: 10.1086/421054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/421054</ArticleId><ArticleId IdType="pmc">PMC1182077</ArticleId><ArticleId IdType="pubmed">15106121</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C., Herranz-Martin S., Karyka E., Liao C., Lewis K., Elsayed W., Lukashchuk V., Chiang S.C., Ray S., Mulcahy P.J., et al. C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat. Neurosci. 2017;20:1225&#x2013;1235. doi: 10.1038/nn.4604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4604</ArticleId><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirtreiter A., Damsma G.E., Cheung A.C.M., Klose D., Grohmann D., Vojnic E., Martin A.C.R., Cramer P., Werner F. Spt4/5 stimulates transcription elongation through the RNA polymerase clamp coiled-coil motif. Nucleic Acids Res. 2010;38:4040&#x2013;4051. doi: 10.1093/nar/gkq135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq135</ArticleId><ArticleId IdType="pmc">PMC2896526</ArticleId><ArticleId IdType="pubmed">20197319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rond&#xf3;n A.G., Garc&#xed;a-Rubio M., Gonz&#xe1;lez-Barrera S., Aguilera A. Molecular evidence for a positive role of Spt4 in transcription elongation. EMBO J. 2003;22:612&#x2013;620. doi: 10.1093/emboj/cdg047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdg047</ArticleId><ArticleId IdType="pmc">PMC140732</ArticleId><ArticleId IdType="pubmed">12554661</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-R., Chang C.-R., Chern Y., Wang T.-H., Hsieh W.-C., Shen W.-C., Chang C.-Y., Chu I.C., Deng N., Cohen S.N., et al. Spt4 is selectively required for transcription of extended trinucleotide repeats. Cell. 2012;148:690&#x2013;701. doi: 10.1016/j.cell.2011.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.12.032</ArticleId><ArticleId IdType="pubmed">22341442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer N.J., Carlomagno Y., Zhang Y.-J., Almeida S., Cook C.N., Gendron T.F., Prudencio M., Van Blitterswijk M., Belzil V., Couthouis J., et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science. 2016;353:708&#x2013;712. doi: 10.1126/science.aaf7791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf7791</ArticleId><ArticleId IdType="pmc">PMC5823025</ArticleId><ArticleId IdType="pubmed">27516603</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman L.D., Prudencio M., Kramer N.J., Martinez-Ramirez L.F., Srinivasan A.R., Lan M., Parisi M.J., Zhu Y., Chew J., Cook C.N., et al. Toxic expanded GGGGCC repeat transcription is mediated by the PAF1 complex in C9orf72-associated FTD. Nat. Neurosci. 2019;22:863&#x2013;874. doi: 10.1038/s41593-019-0396-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0396-1</ArticleId><ArticleId IdType="pmc">PMC6535128</ArticleId><ArticleId IdType="pubmed">31110321</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto B.S., Saxena T., Oliveira R., M&#xe9;ndez-G&#xf3;mez H.R., Cleary J.D., Denes L.T., McConnell O., Arboleda J., Xia G., Swanson M.S., et al. Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9. Mol. Cell. 2017;68:479&#x2013;490e5. doi: 10.1016/j.molcel.2017.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.09.033</ArticleId><ArticleId IdType="pmc">PMC6013302</ArticleId><ArticleId IdType="pubmed">29056323</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R., Nelles D.A., Pirie E., Blue S.M., Marina R.J., Wang H., Chaim I.A., Thomas J.D., Zhang N., Nguyen V., et al. Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. Cell. 2017;170:899&#x2013;912e10. doi: 10.1016/j.cell.2017.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.010</ArticleId><ArticleId IdType="pmc">PMC5873302</ArticleId><ArticleId IdType="pubmed">28803727</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Lee A., Murphy A., Chang J., Zipf A., Cudkowicz M., Atassi N. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph. Lateral Scler. Front. Degener. 2014;15:453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G., Holtzman D.M. Antibody Therapeutics Targeting A&#x3b2; and Tau. Cold Spring Harb. Perspect. Med. 2017;7:a024331. doi: 10.1101/cshperspect.a024331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024331</ArticleId><ArticleId IdType="pmc">PMC5500436</ArticleId><ArticleId IdType="pubmed">28062555</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson&#x2019;s disease. Neuron. 2005;46:857&#x2013;868. doi: 10.1016/j.neuron.2005.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.05.010</ArticleId><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Lehmer C., Michaelsen M., Mori K., Alterauge D., Baumjohann D., Schludi M.H., Greiling J., Farny D., Flatley A., et al. Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol. Med. 2017;9:687&#x2013;702. doi: 10.15252/emmm.201607054.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607054</ArticleId><ArticleId IdType="pmc">PMC5412769</ArticleId><ArticleId IdType="pubmed">28351931</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofani R., Crippa V., Vezzoli G., Rusmini P., Galbiati M., Cicardi M.E., Meroni M., Ferrari V., Tedesco B., Piccolella M., et al. The small heat shock protein B8 (HSPB8) efficiently removes aggregating species of dipeptides produced in C9ORF72-related neurodegenerative diseases. Cell Stress Chaperones. 2018;23:1&#x2013;12. doi: 10.1007/s12192-017-0806-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-017-0806-9</ArticleId><ArticleId IdType="pmc">PMC5741577</ArticleId><ArticleId IdType="pubmed">28608264</ArticleId></ArticleIdList></Reference><Reference><Citation>Licata N.V., Cristofani R., Salomonsson S., Wilson K.M., Kempthorne L., Vaizoglu D., D&#x2019;Agostino V.G., Pollini D., Loffredo R., Pancher M., et al. C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation. EMBO J. 2022;41:e105026. doi: 10.15252/embj.2020105026.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020105026</ArticleId><ArticleId IdType="pmc">PMC8724771</ArticleId><ArticleId IdType="pubmed">34791698</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Hung S.T., Rocha G., Lin S., Linares G.R., Staats K.A., Seah C., Wang Y., Chickering M., Lai J., et al. Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight. 2019;5:e127736. doi: 10.1172/jci.insight.127736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.127736</ArticleId><ArticleId IdType="pmc">PMC6693831</ArticleId><ArticleId IdType="pubmed">31310593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W., Wang S., Zhang Z., Morgens D.W., Hayes L.R., Lee S., Portz B., Xie Y., Nguyen B.V., Haney M.S., et al. CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)n Repeat-Associated Non-AUG Translation. Neuron. 2019;104:885&#x2013;898. doi: 10.1016/j.neuron.2019.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.09.003</ArticleId><ArticleId IdType="pmc">PMC6895427</ArticleId><ArticleId IdType="pubmed">31587919</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W., Wang S., Mestre A.A., Fu C., Makarem A., Xian F., Hayes L.R., Lopez-Gonzalez R., Drenner K., Jiang J., et al. C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2alpha phosphorylation. Nat. Commun. 2018;9:51. doi: 10.1038/s41467-017-02495-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02495-z</ArticleId><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue G.M., Castelli L.M., Ferraiuolo L., Sanchez-Martinez A., Cooper-Knock J., Higginbottom A., Lin Y.-H., Bauer C.S., Dodd J.E., Myszczynska M.A., et al. SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nat. Commun. 2017;8:16063. doi: 10.1038/ncomms16063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms16063</ArticleId><ArticleId IdType="pmc">PMC5504286</ArticleId><ArticleId IdType="pubmed">28677678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Daigle J.G., Cunningham K.M., Coyne A.N., Ruan K., Grima J.C., Bowen K.E., Wadhwa H., Yang P., Rigo F., et al. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018;173:958&#x2013;971.e17. doi: 10.1016/j.cell.2018.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho M.A., Baloh R.H., Chakraverty S., Mayo K., Norton J.B., Levitch D., Hatanpaa K.J., White C.L., 3rd, Bigio E.H., Caselli R., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008;63:535&#x2013;538. doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin V.M., Leverenz J.B., Bekris L.M., Bird T.D., Yuan W., Elman L.B., Clay D., Wood E.M., Chen-Plotkin A.S., Martinez-Lage M., et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416. doi: 10.1016/S1474-4422(08)70071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70071-1</ArticleId><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: Summary and update. Hum. Mutat. 2013;34:812&#x2013;826. doi: 10.1002/humu.22319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordana M.T., Piccinini M., Grifoni S., De Marco G., Vercellino M., Magistrello M., Pellerino A., Buccinna B., Lupino E., Rinaudo M.T. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010;20:351&#x2013;360. doi: 10.1111/j.1750-3639.2009.00284.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2009.00284.x</ArticleId><ArticleId IdType="pmc">PMC8094784</ArticleId><ArticleId IdType="pubmed">19338576</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk T.R., Rousseaux M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R., Tada M., Shiga A., Toyoshima Y., Konno T., Sato T., Nozaki H., Kato T., Horie M., Shimizu H., et al. Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: Evidence for clinico-pathologic subtypes. Acta Neuropathol. Commun. 2016;4:61. doi: 10.1186/s40478-016-0335-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0335-2</ArticleId><ArticleId IdType="pmc">PMC4918136</ArticleId><ArticleId IdType="pubmed">27338935</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Kwong L.K., Sampathu D.M., Trojanowski J.Q., Lee V.M. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: Protein misfolding diseases without amyloidosis. Arch. Neurol. 2007;64:1388&#x2013;1394. doi: 10.1001/archneur.64.10.1388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.10.1388</ArticleId><ArticleId IdType="pubmed">17923623</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F.E. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 2010;7:420&#x2013;429. doi: 10.4161/rna.7.4.12205.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.7.4.12205</ArticleId><ArticleId IdType="pubmed">20639693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A., Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016;138((Suppl. 1)):95&#x2013;111. doi: 10.1111/jnc.13625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13625</ArticleId><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., Zago P., D&#x2019;Ambrogio A., Xu Y.F., Petrucelli L., Buratti E., Baralle F.E. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci. 2008;121:3778&#x2013;3785. doi: 10.1242/jcs.038950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer B.C., Schuck T., Wheeler J.M., Robinson L.C., Trojanowski J.Q., Lee V.M., Schellenberg G.D. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119:409&#x2013;419. doi: 10.1007/s00401-010-0659-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P.E., Zhang Y.J., Roberts C.M., Saldi T., Hutter H., Buratti E., Petrucelli L., Link C.D. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum. Mol. Genet. 2010;19:3206&#x2013;3218. doi: 10.1093/hmg/ddq230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq230</ArticleId><ArticleId IdType="pmc">PMC2908471</ArticleId><ArticleId IdType="pubmed">20530643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Lin L., Tradewell M.L., Dion P.A., Bercier V., Bourgouin P., Rochefort D., Bel Hadj S., Durham H.D., Vande Velde C., et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2010;19:671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2010;107:3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert. Opin. Ther. Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M., et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G., et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne Alyssa N., Baskerville V., Zaepfel Benjamin L., Dickson Dennis W., Rigo F., Bennett F., Lusk C.P., Rothstein Jeffrey D. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci. Transl. Med. 2021;13:eabe1923. doi: 10.1126/scitranslmed.abe1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe1923</ArticleId><ArticleId IdType="pmc">PMC9022198</ArticleId><ArticleId IdType="pubmed">34321318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A.L., Shum C., Scotter E.L., Abdelgany A., Sardone V., Wright J., Lee Y.B., Chen H.J., Bilican B., Carrasco M., et al. Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS ONE. 2014;9:e91269. doi: 10.1371/journal.pone.0091269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0091269</ArticleId><ArticleId IdType="pmc">PMC3961241</ArticleId><ArticleId IdType="pubmed">24651281</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z.Y., Ieraci A., Teng H., Dall H., Meng C.X., Herrera D.G., Nykjaer A., Hempstead B.L., Lee F.S. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J. Neurosci. 2005;25:6156&#x2013;6166. doi: 10.1523/JNEUROSCI.1017-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1017-05.2005</ArticleId><ArticleId IdType="pmc">PMC1201519</ArticleId><ArticleId IdType="pubmed">15987945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tann J.Y., Wong L.W., Sajikumar S., Ibanez C.F. Abnormal TDP-43 function impairs activity-dependent BDNF secretion, synaptic plasticity, and cognitive behavior through altered Sortilin splicing. EMBO J. 2019;38:e100989. doi: 10.15252/embj.2018100989.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018100989</ArticleId><ArticleId IdType="pmc">PMC6396160</ArticleId><ArticleId IdType="pubmed">30692134</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold H.C., Jackson K.L., Arora A., Weskamp K., Tank E.M., Li X., Miguez R., Dayton R.D., Tamir S., Klein R.L., et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci. Rep. 2018;8:4606. doi: 10.1038/s41598-018-22858-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22858-w</ArticleId><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H., Gao K., Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 2014;10:337&#x2013;348. doi: 10.1038/nrneurol.2014.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId><ArticleId IdType="pubmed">24840975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007. doi: 10.1016/S1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumer D., Hilton D., Paine S.M., Turner M.R., Lowe J., Talbot K., Ansorge O. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:611&#x2013;618. doi: 10.1212/WNL.0b013e3181ed9cde.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ed9cde</ArticleId><ArticleId IdType="pmc">PMC2931770</ArticleId><ArticleId IdType="pubmed">20668261</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S., Neumann M., Rosenbohm A., Birve A., Volk A.E., Weishaupt J.H., Meyer T., Muller U., Andersen P.M., Ludolph A.C. Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: A clinico-genetic study in Germany. Eur. J. Neurol. 2013;20:540&#x2013;546. doi: 10.1111/ene.12031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12031</ArticleId><ArticleId IdType="pubmed">23217123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J., Appel S., Baloh R.H., Barohn R., Brooks B.R., Elman L., Floeter M.K., Henderson C., Lomen-Hoerth C., Macklis J.D., et al. Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph. Lateral Scler. Front. Degener. 2013;14((Suppl. 1)):5&#x2013;18. doi: 10.3109/21678421.2013.778548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.778548</ArticleId><ArticleId IdType="pmc">PMC3779649</ArticleId><ArticleId IdType="pubmed">23678876</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H.A., Mackenzie I.R. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain J. Neurol. 2009;132:2922&#x2013;2931. doi: 10.1093/brain/awp214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp214</ArticleId><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.Y., Pan L., Su S.C., Quinn E.J., Sasaki M., Jimenez J.C., Mackenzie I.R., Huang E.J., Tsai L.H. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci. 2013;16:1383&#x2013;1391. doi: 10.1038/nn.3514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3514</ArticleId><ArticleId IdType="pmc">PMC5564396</ArticleId><ArticleId IdType="pubmed">24036913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig S., Kong G., Mannen T., Sadowska A., Kobelke S., Blythe A., Knott G.J., Iyer K.S., Ho D., Newcombe E.A., et al. Prion-like domains in RNA binding proteins are essential for building subnuclear paraspeckles. J. Cell Biol. 2015;210:529&#x2013;539. doi: 10.1083/jcb.201504117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201504117</ArticleId><ArticleId IdType="pmc">PMC4539981</ArticleId><ArticleId IdType="pubmed">26283796</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Scotter E.L., Nishimura A.L., Troakes C., Mitchell J.C., Kathe C., Urwin H., Manser C., Miller C.C., Hortobagyi T., et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 2013;22:2676&#x2013;2688. doi: 10.1093/hmg/ddt117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt117</ArticleId><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasayama H., Shimamura M., Tokuda T., Azuma Y., Yoshida T., Mizuno T., Nakagawa M., Fujikake N., Nagai Y., Yamaguchi M. Knockdown of the Drosophila fused in sarcoma (FUS) homologue causes deficient locomotive behavior and shortening of motoneuron terminal branches. PLoS ONE. 2012;7:e39483. doi: 10.1371/journal.pone.0039483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039483</ArticleId><ArticleId IdType="pmc">PMC3378546</ArticleId><ArticleId IdType="pubmed">22724023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J.C., McGoldrick P., Vance C., Hortobagyi T., Sreedharan J., Rogelj B., Tudor E.L., Smith B.N., Klasen C., Miller C.C., et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273&#x2013;288. doi: 10.1007/s00401-012-1043-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1043-z</ArticleId><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Yi F., Fu L., Yang J., Wang S., Wang Z., Suzuki K., Sun L., Xu X., Yu Y., et al. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. Protein Cell. 2017;8:365&#x2013;378. doi: 10.1007/s13238-017-0397-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0397-3</ArticleId><ArticleId IdType="pmc">PMC5413600</ArticleId><ArticleId IdType="pubmed">28401346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhinge A., Namboori S.C., Zhang X., VanDongen A.M.J., Stanton L.W. Genetic Correction of SOD1 Mutant iPSCs Reveals ERK and JNK Activated AP1 as a Driver of Neurodegeneration in Amyotrophic Lateral Sclerosis. Stem Cell Rep. 2017;8:856&#x2013;869. doi: 10.1016/j.stemcr.2017.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.02.019</ArticleId><ArticleId IdType="pmc">PMC5390134</ArticleId><ArticleId IdType="pubmed">28366453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo W., Mitra J., Hegde P.M., Vandoorne T., Eckelmann B.J., Mitra S., Tomkinson A.E., Van Den Bosch L., Hegde M.L. Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in Amyotrophic Lateral Sclerosis. Nat. Commun. 2018;9:3683. doi: 10.1038/s41467-018-06111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06111-6</ArticleId><ArticleId IdType="pmc">PMC6134028</ArticleId><ArticleId IdType="pubmed">30206235</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., Veys K., Guo W., Sicart A., Vints K., Swijsen A., Moisse M., Eelen G., Gounko N.V., Fumagalli L., et al. Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. Nat. Commun. 2019;10:4147. doi: 10.1038/s41467-019-12099-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12099-4</ArticleId><ArticleId IdType="pmc">PMC6742665</ArticleId><ArticleId IdType="pubmed">31515480</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordovas L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Bucelli R.C., Andrews J.A., Otto M., Farahany N.A., Harrington E.A., Chen W., Mitchell A.A., et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: The ATLAS Study. Neurotherapeutics. 2022 doi: 10.1007/s13311-022-01237-4. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J. Presymptomatic studies in ALS: Rationale, challenges, and approach. Neurology. 2012;79:1732&#x2013;1739. doi: 10.1212/WNL.0b013e31826e9b1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9b1d</ArticleId><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Lombardi V., Jeromin A., Bowser R., Andersen P.M., Malaspina A. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Front. Degener. 2019;20:538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V., Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>